Introduction {#section5-1753466620942417}
============

Bacterial co-infection worsens the clinical course and outcome in patients with influenza. Postmortem analysis of histopathological samples collected during the 1918 Spanish pandemic influenza revealed typical features of acute bacterial pneumonia, and 95.8% of the lung cultures tested positive for bacteria.^[@bibr1-1753466620942417]^ In the 2009 global pandemic H1N1 influenza A virus infection, 18--34% of patients admitted to intensive care units (ICUs) developed bacterial coinfection,^[@bibr2-1753466620942417][@bibr3-1753466620942417][@bibr4-1753466620942417]--[@bibr5-1753466620942417]^ and their in-hospital mortality rate was as high as 30.9%.^[@bibr5-1753466620942417]^

Hospital-acquired pneumonia and ventilator-associated pneumonia (VAP) cause a significant increase in health-care resource utilization and prolong hospitalization. A meta-analysis showed that VAP increased both ICU stay and hospital stay by 8.7 and 11.5 days, respectively.^[@bibr6-1753466620942417]^ In patients with acute respiratory failure developing subsequent VAP, 47% of the isolated pathogens were Gram-negative bacilli (GNB), such as *Pseudomonas aeruginosa, Acinetobacter baumannii* and *Stenotrophomonas maltophilia*.^[@bibr7-1753466620942417]^ Among patients with influenza pneumonia and acute respiratory failure, 26% later developed VAP, and the most commonly identified pathogens were GNB, including *A. baumannii* and *P. aeruginosa*.^[@bibr2-1753466620942417]^

To date, however, limited data are available on patients with severe influenza infection and nosocomial lower respiratory tract infection (NLRTI), as well as their clinical impact. The present study aimed to describe the clinical characteristics, risk factors and outcomes of patients with severe influenza-related acute respiratory distress syndrome (ARDS) having NLRTI.

Methods {#section6-1753466620942417}
=======

Study design, setting and participants {#section7-1753466620942417}
--------------------------------------

This multicenter retrospective observational study was conducted in Taiwan. Eight medical centers, including four hospitals in northern Taiwan, two hospitals in central Taiwan and two hospitals in southern Taiwan, participated in the clinical investigation. The data collection period was from 1 January 2016 to 31 March 2016 in all ICUs. All patients were screened for eligibility if the diagnosis of virology-proven influenza was confirmed by the Taiwan Centers for Disease Control on the basis of a rapid influenza diagnostic test, reverse transcription-polymerase chain reaction, or viral culture. We enrolled patients with influenza-related ARDS requiring intubation and mechanical ventilation. The severity of ARDS was graded according to the Berlin definition,^[@bibr8-1753466620942417]^ and ARDS was defined by the acute onset of respiratory distress within 1 week, diffuse opacities in both lungs confirmed using imaging modalities, no evidence of cardiogenic pulmonary edema, and hypoxemia with an arterial partial pressure of oxygen/fraction of inspired oxygen ratio \<300 with positive end-expiratory pressure ⩾5 cm H~2~O.

The study protocol was approved by the Institutional Review Boards of all eight hospitals (Taipei Veterans General Hospital, 2016-05-020CC; Taichung Veterans General Hospital, CE16093A; Tri-Service General Hospital, 1-105-05-086; National Taiwan University Hospital, 201605036RIND; Chang Gung Memorial Hospital, 201600988B0; China Medical University Hospital, 105-REC2-053(FR); Kaohsiung Medical University Hospital, KUMHIRB-E(I)-20170097; and Kaohsiung Chang Gung Memorial Hospital, 201600988B0). The requirement for written informed consent was waived because all patient information was anonymized and de-identified during data recording.

Data collection and measurements {#section8-1753466620942417}
--------------------------------

Demographic data including age, sex, body mass index and comorbidities along with critical illness data, such as laboratory results, severity scores and ARDS severity upon initial presentation of influenza-related ARDS, were recorded. Important interventions performed in the ICU, including extracorporeal membrane oxygenation (ECMO), prone position, renal replacement therapy and use of vasopressors, sedatives, neuromuscular blockers and glucocorticoids within 14 days after influenza-related ARDS, were analyzed. The outcome measures encompassed development of NLRTI, in-hospital mortality, ICU stay, hospital stay and duration on mechanical ventilation. Length of hospital stay was calculated from onset of influenza-related ARDS to discharge or death. We recorded the Acute Physiology and Chronic Health Evaluation II (APACHE II) scores^[@bibr9-1753466620942417]^ and Sequential Organ Failure Assessment (SOFA) scores^[@bibr10-1753466620942417]^ on the day of ICU admission and followed up the SOFA scores up to 1 week after hospitalization.

Immunosuppressant use before influenza infection was defined as an oral prednisolone equivalent dose \>5 mg/day or \>150 mg cumulative dose or other immunosuppressant usage within 1 month before influenza infection.

Patients with bacterial community-acquired pneumonia (CAP) at the onset of ARDS were excluded. The diagnosis of CAP was in accordance with the guideline developed by the American Thoracic Society and Infectious Disease Society of North America.^[@bibr11-1753466620942417],[@bibr12-1753466620942417]^ Antibiotics prescribed upon diagnosis of influenza-related ARDS and lasting for at least 5 consecutive days was also defined as the presence of CAP.

NLRTI was suspected in patients meeting the criteria of ventilator-associated events defined by the Centers for Disease Control and Prevention.^[@bibr13-1753466620942417]^ Evidence of infection was confirmed by two intensivists (KCK and CCS) in agreement with the NLRTI after a detailed chart review of symptoms and vital signs, laboratory data and chest images. Newly developed or progressive respiratory symptoms, unstable vitals, elevated white blood cell counts or left shift, C-reactive protein or procalcitonin level, and new infiltrates on chest radiographs were suggestive of NLRTI. The presence of pathogenic bacteria in the respiratory specimen obtained 48 h after hospitalization and the administration of appropriate antibiotic treatment for at least 7 days were required for confirming a clinical diagnosis of NLRTI. The respiratory specimen was obtained from tracheal aspirates, bronchoalveolar lavage fluids, protected sheath brushing samples or biopsied tissues.

The primary outcome was development of NLRTI. Other outcome measurements were in-hospital mortality, ICU days, hospital days, and duration of mechanical ventilation.

Statistical analysis {#section9-1753466620942417}
--------------------

The results were presented as mean ± standard deviation, median with interquartile range, or number (%) whenever appropriate. We used the Kolmogorov--Smirnov and Shapiro--Wilk tests to examine the normality of continuous variables. Independent *t* tests were used to compare normally distributed continuous variables, and the Mann--Whitney *U* test was used to compare non-normally distributed continuous variables. We used the Pearson χ^2^ test or Fisher's exact test to compare categorical variables. Variables showing significant differences between groups were entered into univariate and multivariate logistic regression analyses by using the enter method to determine factors that independently predict NLRTI. Odds ratios (ORs) and 95% confidence intervals (CIs) were also calculated. A *p* value \< 0.05 was considered statistically significant. All statistical analyses were performed using IBM SPSS Statistics for Windows/Macintosh, Version 22.0 (IBM Corp., Armonk, NY, USA) and MedCalc for Windows, Version 17.9.4 (MedCalc Software bvba, Mariakerke, Belgium).

Results {#section10-1753466620942417}
=======

During the study period, we enrolled 316 patients having complete medical records with virology-proven complicated influenza. Patients were excluded if they had not received invasive mechanical ventilation, did not have a diagnosis of ARDS or confirmed bacterial CAP. Finally, 250 patients were eligible for further analysis ([Figure 1](#fig1-1753466620942417){ref-type="fig"}).

![Flow chart of the study.\
^a^Virology-proven methods include the rapid influenza diagnostic test, reverse transcription-polymerase chain reaction and virus culture.\
ARDS, acute respiratory distress syndrome; ICU, intensive care unit; NLRTI, nosocomial lower respiratory tract infection.](10.1177_1753466620942417-fig1){#fig1-1753466620942417}

In [Table 1](#table1-1753466620942417){ref-type="table"}, the patients' characteristics and clinical data are summarized. Most respiratory specimens of NLRTI (81.9%) were collected from tracheal aspirates. In patients with NLRTI, more immunosuppressant use before influenza infection, greater need of extracorporeal membrane oxygenation (ECMO) support, more use of vasopressors and larger steroid dosage were observed.

###### 

Characteristics of the 250 subjects with influenza-related ARDS categorized according to NLRTI.

![](10.1177_1753466620942417-table1)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                                       NLRTI\         Without NLRTI\   *p* value
                                                                                                                                                       *n* = 72       *n* = 178        
  ---------------------------------------------------------------------------------------------------------------------------------------------------- -------------- ---------------- -----------
  **Baseline data**                                                                                                                                                                    

   Age (years)                                                                                                                                         61.0 ± 13.6    58.8 ± 14.8      0.282

   Male                                                                                                                                                47 (65.3%)     110 (61.8%)      0.606

   Body mass index (kg/m^2^)                                                                                                                           25.1 ± 4.9     25.3 ± 5.7       0.789

   Malignancy                                                                                                                                          11 (15.3%)     21 (11.8%)       0.456

   Type II diabetes mellitus                                                                                                                           22 (30.6%)     51 (28.7%)       0.764

   Liver cirrhosis                                                                                                                                     8 (11.1%)      24 (13.5%)       0.611

   Cerebrovascular disease                                                                                                                             5 (6.9%)       15 (8.4%)        0.696

   End-stage renal disease                                                                                                                             6 (8.3%)       9 (5.1%)         0.379

   Congestive heart failure                                                                                                                            5 (6.9%)       19 (10.7%)       0.365

   Immunosuppressant use before influenza infection^[a](#table-fn2-1753466620942417){ref-type="table-fn"}^                                             9 (12.5%)      5 (2.8%)         0.005

  **Subtypes of influenza**                                                                                                                                                            

   Type A                                                                                                                                              57 (79.2%)     141 (79.2%)      0.989

   Type B                                                                                                                                              6 (8.3%)       14 (7.9%)        

   Positive, unknown subtype                                                                                                                           9 (12.5%)      23 (12.9%)       

  **Laboratory data**                                                                                                                                                                  

   Albumin (mg/dL)                                                                                                                                     2.8 ± 0.5      2.8 ± 0.6        0.770

   Serum C-reactive protein (mg/dL)                                                                                                                    15.4 ± 9.4     15.3 ± 10.6      0.959

   Serum lactate level (mg/dL)                                                                                                                         24.8 ± 24.3    31.9 ± 41.5      0.200

  **Severity scores**                                                                                                                                                                  

   APACHE II                                                                                                                                           23.7 ± 8.5     23.6 ± 8.5       0.914

   SOFA score                                                                                                                                                                          

    Day 1                                                                                                                                              11.7 ± 3.9     10.9 ± 2.9       0.494

    Day 3                                                                                                                                              10.4 ± 5.0     10.9 ± 3.2       0.733

    Day 7                                                                                                                                              9.0 ± 3.9      8.8 ± 2.9        0.878

   PaO~2~/FiO~2~                                                                                                                                       102.0 ± 66.3   107.9 ± 61.1     0.510

   ARDS^[b](#table-fn3-1753466620942417){ref-type="table-fn"}^                                                                                                                         0.920

    Mild                                                                                                                                               8 (11.1%)      19 (10.7%)       

    Moderate to severe                                                                                                                                 64 (88.9%)     159 (89.3%)      

  **Management**                                                                                                                                                                       

   ECMO^[c](#table-fn4-1753466620942417){ref-type="table-fn"}^                                                                                         21 (29.2%)     26 (14.6%)       0.008

   Prone position^[c](#table-fn4-1753466620942417){ref-type="table-fn"}^                                                                               17 (23.6%)     41 (23.0%)       0.922

   Renal replacement therapy^[c](#table-fn4-1753466620942417){ref-type="table-fn"},[d](#table-fn5-1753466620942417){ref-type="table-fn"}^              5 (6.9%)       25 (14.0%)       0.118

   Vasopressor^[c](#table-fn4-1753466620942417){ref-type="table-fn"}^                                                                                  46 (63.9%)     88 (49.4%)       0.038

   Sedation^[c](#table-fn4-1753466620942417){ref-type="table-fn"}^                                                                                     57 (79.2%)     128 (71.9%)      0.236

   Neuromuscular blockade^[c](#table-fn4-1753466620942417){ref-type="table-fn"}^                                                                       46 (63.9%)     109 (61.2%)      0.696

   Steroid use^[c](#table-fn4-1753466620942417){ref-type="table-fn"}^                                                                                  43 (59.7%)     116 (65.2%)      0.418

   Mean steroid dosage^[c](#table-fn4-1753466620942417){ref-type="table-fn"}^ (mg/kg per day)^[e](#table-fn6-1753466620942417){ref-type="table-fn"}^   1.6 ± 2.9      1.0 ± 1.4        0.017
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data are presented as mean ± standard deviation and number (%).

Oral prednisolone equivalent dosage \> 5 mg/day or  \> 150 mg cumulative dose within 1 month before influenza infection; or regular treatment using other immunosuppressants within 1 month before influenza infection.

In accordance with the Berlin definition.

In our cohorts, 20 (95.2%) out of 21 patients with NLRTI received ECMO before development of NLRTI. Other managements, including prone position, renal replacement therapy, vasopressors, sedatives, neuromuscular blockade and steroid, were all initiated before NLRTI.

Excluding those with end-stage renal disease receiving regular hemodialysis.

In NLRTI group, mean steroid dosage was calculated only before NLRTI. In patients without NLRTI, mean steroid dosage was calculated from steroid cumulative dosage for 14 days *via* prednisolone equivalent dose (mg) after ARDS.

APACHE II, Acute Physiology and Chronic Health Evaluation; ARDS, acute respiratory distress syndrome; ECMO, extracorporeal membrane oxygenation; FiO~2~, fraction of inspired oxygen; NLRTI, nosocomial lower respiratory tract infection; PaO~2~, arterial partial pressure of oxygen; SOFA, Sequential Organ Failure Assessment.

The patients with NLRTI also had worse outcomes, including more in-hospital mortality, prolonged hospital and ICU stays and longer duration on mechanical ventilation ([Table 2](#table2-1753466620942417){ref-type="table"}). The median time of acquiring NLRTI was 11 days, and the most commonly isolated pathogenic bacterium was *A. baumannii*, which was resistant to carbapenem in 96.6% of cases (see [Supplemental Material Table 1](https://journals.sagepub.com/doi/suppl/10.1177/1753466620942417) online).

###### 

Outcomes of the 250 patients with influenza-related acute respiratory distress syndrome categorized according to NLRTI.

![](10.1177_1753466620942417-table2)

  -------------------------------------------------------------------------
                                 NLRTI\        Without NLRTI\   *p* value
                                 *n* = 72      *n* = 178        
  ------------------------------ ------------- ---------------- -----------
   In-hospital mortality         34 (47.2%)    51 (28.7%)       \<0.001

   ICU stay (days)               30.4 ± 21.5   15.1 ± 13.0      \<0.001

   Hospital stay (days)          47.9 ± 36.7   25.6 ± 18.6      \<0.001

   Ventilation duration (days)   26.8 ± 18.3   13.6 ± 11.0      \<0.001
  -------------------------------------------------------------------------

Data are presented as mean ± standard deviation and number (%).

ICU, intensive care unit; NLRTI, nosocomial lower respiratory tract infection.

To further clarify the clinical risk factors for NLRTI among patients with influenza-related ARDS, we used univariate and multivariate logistic regression analyses ([Table 3](#table3-1753466620942417){ref-type="table"}). Immunosuppressant use before influenza infection (OR, 5.669; 95% CI, 1.770--18.154), ECMO use (OR, 2.440; 95% CI, 1.214--4.904) and mean steroid dosage after influenza-related ARDS (OR, 1.209; 95% CI, 1.038--1.407) were significant variables. The Hosmer--Lemeshow test in our multivariate logistic regression analysis model showed it was a good fit (*p* = 0.189). In the Cox proportional hazards model, we also found that patients with immunosuppressant use before influenza infection, ECMO use after ARDS, and larger steroid dosage after ARDS had a higher probability of developing NLRTI during their clinical course \[[Figure 2(A)](#fig2-1753466620942417){ref-type="fig"} to ([C](#fig2-1753466620942417){ref-type="fig"})\].

###### 

Risk factors for nosocomial lower respiratory tract infection according to univariate and multivariate logistic regression analyses.

![](10.1177_1753466620942417-table3)

                                                                                                             Univariate   Multivariate                                    
  ---------------------------------------------------------------------------------------------------------- ------------ --------------- ------- ------- --------------- -------
  Immunosuppressant use before influenza infection^[a](#table-fn10-1753466620942417){ref-type="table-fn"}^   4.943        1.596--15.311   0.006   5.669   1.770--18.154   0.003
  ECMO use                                                                                                   2.407        1.248--4.642    0.009   2.440   1.214--4.904    0.012
  Vasopressor user                                                                                           1.809        1.030--3.179    0.039   1.567   0.853--2.879    0.148
  Mean steroid dosage after ARDS (kg/mg per day)                                                             1.171        1.019--1.347    0.026   1.209   1.038--1.407    0.015

Oral prednisolone equivalent dosage \>5 mg/day or \>150 mg cumulative dose within 1 month before influenza infection; using other immunosuppressants for more than 1 month.

ARDS, acute respiratory distress syndrome; ECMO, extracorporeal membrane oxygenation.

![Cox proportional hazard model for survival estimates by clinical risk factors. (A) Survival estimates for development of nosocomial lower respiratory tract infection (NLRTI) in influenza-related acute respiratory distress syndrome (ARDS) stratified by immunosuppressant use before influenza. Immunosuppressant use before influenza had significantly more NLRTI (*p* = 0.0022). (B) Survival estimates for development of NLRTI in influenza-related ARDS stratified by extracorporeal membrane oxygenation (ECMO) use. ECMO group had significantly more NLRTI (*p* = 0.0121). (C) Survival estimates for development of NLRTI in influenza-related ARDS stratified by mean steroid dosage after ARDS. Mean prednisolone equivalent dosage more than 2 mg/kg per day after ARDS had significantly more NLRTI (*p* = 0.0014).](10.1177_1753466620942417-fig2){#fig2-1753466620942417}

In our cohort, liver cirrhosis, more severe clinical condition at presentation and during hospitalization, ECMO use, and development of NLRTI were associated with in-hospital mortality ([Supplemental Tables 2 and 3](https://journals.sagepub.com/doi/suppl/10.1177/1753466620942417)).

Discussion {#section11-1753466620942417}
==========

The aim of this study was to explore the clinical features of NLRTI in severe influenza-related ARDS. Multivariate regression analysis showed that immunosuppressant use before influenza infection, ECMO use after ARDS, and larger steroid dosage after influenza-related ARDS were predictors for NLRTI. We also found that patients with NLRTI had poorer outcomes, including higher mortality, longer ICU and hospital stays and longer duration on mechanical ventilation. To our knowledge, this is the first study to report the risk factors associated with NLRTI in severe influenza-related ARDS.

To date, few studies have investigated the incidence of nosocomial infections in patients with severe influenza. A report on the 2009 H1N1 pandemic in Argentina showed that 25% of patients had pneumonia on admission and 26% of patients developed VAP. The mortality rate in the VAP group was 45.2%.^[@bibr2-1753466620942417]^ Similarly, our multicenter data showed that 28.8% of patients with influenza-related ARDS had NLRTI, and the in-hospital mortality rate was 47.2%.

Bacterial co-infection in patients with influenza resulted in the utilization of more medical resources. During the 2009 Spanish H1N1 influenza pandemic, patients in the co-infection group needed more invasive mechanical ventilation and vasopressor use.^[@bibr4-1753466620942417]^ Our data also showed that the NLRTI group required more ECMO support and vasopressor use.

Several risk factors for bacterial co-infection in patients with influenza have been identified. Elderly patients aged more than 65 years old, preschoolers and pregnant women, as well as patients with obesity, chronic pulmonary diseases, cardiovascular disorders, hepatic dysfunction, renal insufficiency, diabetes and an immunocompromised status had a higher risk of bacterial coinfection.^[@bibr14-1753466620942417]^ During the 2009 H1N1 influenza pandemic in Spain, older patients with higher APACHE II and SOFA scores had a higher risk of bacterial coinfection.^[@bibr4-1753466620942417]^ In our cohort, we also noted that immunosuppressant use before influenza infection increased the risk of NLRTI.

Corticosteroid use is associated with various adverse events, including glaucoma, hyperglycemia, cardiovascular diseases, osteoporosis and avascular necrosis of the bone.^[@bibr15-1753466620942417][@bibr16-1753466620942417][@bibr17-1753466620942417][@bibr18-1753466620942417]--[@bibr19-1753466620942417]^ In addition, infection is of the utmost concern and is well documented.^[@bibr20-1753466620942417]^ Several observational studies utilizing big databases found that even under a prednisone equivalent dose as low as 5 mg/day, patients with rheumatoid arthritis had an increased risk of bacterial infection with a hazard ratio ranging from 1.32 to 1.78.^[@bibr21-1753466620942417],[@bibr22-1753466620942417]^ Wolf *et al*. reported an increased risk for pneumonia requiring hospitalization in patients with rheumatoid arthritis on a prednisone dose of 5 mg/day.^[@bibr23-1753466620942417]^ Our result is also consistent with these findings.

The incidence of VAP in patients receiving ECMO ranged from 15.8% to 74%.^[@bibr24-1753466620942417][@bibr25-1753466620942417]--[@bibr26-1753466620942417]^ ECMO itself was an independent risk factor for both pneumonia and other infections in patients receiving heart transplantation.^[@bibr27-1753466620942417]^ A possible mechanism underlying ECMO-related infection is the decreased monocyte response to pathogens induced by extracorporeal support.^[@bibr28-1753466620942417]^ The impacts of VAP on patients receiving ECMO included longer ECMO duration and increased mortality.^[@bibr29-1753466620942417]^ Our study was the first to show the association between ECMO and NLRTI in patients with severe influenza-related ARDS.

A meta-analysis showed that adjunctive therapy with glucocorticoids was harmful to patients with influenza. Steroid use was associated with an increased risk of mortality (OR, 3.06; 95% CI, 1.58--5.92) in patients with influenza.^[@bibr30-1753466620942417]^ Although no randomized trials have as yet assessed the effect of glucocorticoids on influenza-related ARDS, experiences from treating H1N1 influenza-related ARDS demonstrated that early corticosteroid use is strongly associated with mortality. Patients receiving steroids had more frequent nosocomial pneumonia and showed a trend towards a longer duration of mechanical ventilation. In our study, we also found that larger steroid dosage after influenza-related ARDS increased the risk of NLRTI in such patients.

The pathogens involved in community-acquired bacterial co-infection and nosocomial infection are different. *Streptococcus pneumoniae, P. aeruginosa* and *Staphylococcus aureus* were the most commonly encountered bacteria in the community setting.^[@bibr4-1753466620942417],[@bibr5-1753466620942417]^ In contrast, in patients with severe influenza developing subsequent VAP, *A. baumannii* and *P. aeruginosa* were the most frequent causative organisms. *A. baumannii* was isolated from 29 respiratory specimens collected from our NLRTI group, and it was also the most commonly found microorganism in our patients. Notably, nearly all of the isolated *A. baumannii* bacteria in our series were resistant to carbapenem. This poses a great challenge to our clinicians when prescribing appropriate empiric antibiotics to patients in the NLRTI group.

This study has several limitations. First, this was a retrospective cohort study; therefore, some medical data might be missing. For example, the relative low percentage of sedatives use in our cohort reflected lack of complete medications records. Some patients might be treated with pain control or antipsychotics. Second, the true incidence of nosocomial pneumonia remains uncertain. Owing to the retrospective nature of this study, confirming hospital-acquired pneumonia was difficult. Quantitative cultures from respiratory specimens were not fully available in our cohort. However, NLRTI could serve as a surrogate for clinicians to understand the disease course of severe influenza and to help identify patients at a high risk of bacterial infection. Third, although our study focused on bacterial NLRTI, emerging opportunistic infections, such as those caused by *Aspergillus* sp. or *Candida* sp., should also be considered and preemptive diagnosis and treatment should be mandatory. Fourth, although some patients received steroid treatment during hospitalization, whether it was used for ARDS or other indications could not be analyzed. Fifth, the management strategy of influenza-related ARDS might not be standardized between different study sites. Finally, our study concentrated on patients with influenza-related ARDS requiring invasive mechanical ventilation; therefore, whether the results can be applied to patients with less severe influenza remains unknown. To further understand nosocomial bacterial infections, a well-designed prospective clinical study is needed.

Conclusion {#section12-1753466620942417}
==========

This study found that immunosuppressant use before influenza infection, ECMO use, and larger steroid dosage after influenza-related ARDS independently predict NLRTI in influenza-related ARDS. Moreover, NLRTI results in poorer outcomes in patients with severe influenza.
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